Valued Wealth Advisors LLC Sells 148 Shares of Johnson & Johnson (NYSE:JNJ)

Valued Wealth Advisors LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 17.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 691 shares of the company’s stock after selling 148 shares during the quarter. Valued Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $100,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. McLean Asset Management Corp increased its holdings in Johnson & Johnson by 6.2% during the 4th quarter. McLean Asset Management Corp now owns 3,390 shares of the company’s stock worth $490,000 after purchasing an additional 198 shares during the period. waypoint wealth counsel lifted its holdings in shares of Johnson & Johnson by 4.0% in the 4th quarter. waypoint wealth counsel now owns 5,092 shares of the company’s stock worth $736,000 after buying an additional 196 shares during the period. Union Bancaire Privee UBP SA bought a new position in shares of Johnson & Johnson during the 4th quarter worth $85,886,000. Apexium Financial LP increased its stake in shares of Johnson & Johnson by 108.1% during the fourth quarter. Apexium Financial LP now owns 21,679 shares of the company’s stock valued at $3,135,000 after buying an additional 11,262 shares during the period. Finally, Capital Asset Advisory Services LLC raised its holdings in shares of Johnson & Johnson by 2.1% in the fourth quarter. Capital Asset Advisory Services LLC now owns 30,252 shares of the company’s stock valued at $4,362,000 after acquiring an additional 631 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Citigroup cut their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research note on Thursday, January 23rd. Wolfe Research began coverage on Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 target price on the stock. Leerink Partners decreased their price objective on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $170.44.

Insider Transactions at Johnson & Johnson

In related news, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ opened at $152.78 on Friday. The firm has a market capitalization of $367.82 billion, a PE ratio of 22.97, a price-to-earnings-growth ratio of 2.45 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The company’s fifty day moving average price is $147.73 and its 200-day moving average price is $156.10. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same period in the prior year, the company earned $2.29 earnings per share. The company’s revenue was up 5.3% on a year-over-year basis. On average, equities research analysts predict that Johnson & Johnson will post 10.56 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.25%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.